You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥-B(02137.HK)更新多個藥物研究進展
騰盛博藥-B(02137.HK)公布,公司正在進行的的HBV治療候選藥物臨床組合BRII-179(VBI-2601)和BRII-835(VIR-2218)的2期多區域臨床試驗聯合研究中,患者已完成治療。公司完成了一項2期聯合試驗第一部分的患者入組,預計將在2023年第三季度取得頂線結果。公司戰略開發合作夥伴Vir Biotechnology, Inc.正在進行的2期單克隆抗體siRNA聯合療法治療乙型肝炎(MARCH)試驗B部分的初始數據預計將在2023年下半年獲得,該試驗部分將對BRII-835(VIR-2218)和BRII-877(VIR-3434)與PEG-IFN-α三聯用藥進行評估,包括確定劑量和治療持續時間。 公司亦正著手準備在2023年初啟動產後抑鬱症BRII-296治療PPD的2期研究;基於一項已完成的1期研究的PK數據,公司已決定停止治療HIVBRII-778的開發,該藥物正在作為潛在長效HIV感染聯合療法的一部分進行評估。公司正在探索合作機會,以繼續開發BRII-732作為HIV 1型患者潛在的每周一次的口服長效聯合治療方案。 另外,BRII-672有潛力成為首個針對碳青黴烯類耐藥革蘭氏陰性菌的複雜性尿路感染的口服治療方案。2022年12月,公司向中國國家藥品監督管理局提交了首個新藥臨床試驗前申請,尋求關於BRII-672在中國開發計劃的註冊監管指導。 公司的戰略合作夥伴AN2 Therapeutics, Inc.預計將在2023年中旬完成評估BRII-658(epetraborole)治療由鳥分枝桿菌複合體(MAC)引起的治療難治性肺病的關鍵2/3期臨床試驗的2期部分的入組,並計劃此後立即開始該試驗的3期部分入組。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account